Navigation Links
SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
Date:3/19/2009

plant seeds to USP and EP standards and finally, we have obtained regulatory approval in the US and Europe to administer SBS 1000 in a phase I/II clinical trial, where our insulin was been found to be biologically active without any unexpected adverse reactions," commented James Szarko, Chief Executive Officer at SemBioSys. "We are continuing optimization work targeted at streamlining the production process to further improve cost of goods."

About SemBioSys

Calgary, Alberta-based SemBioSys is a world leader in manufacturing high-value proteins and oils in plant seeds. With its unique, proprietary platform, SemBioSys provides partners with product enablement, exceptionally low cost and unprecedented scalability. The Company applies this platform with high selectivity to opportunities where it has a unique competitive advantage. Since its inception, SemBioSys has produced more than 50 non-native proteins and oils using its patented seed technology, demonstrating applicability across a broad range of industries such as pharmaceuticals, personal care and industrial products. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI(Milano), a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could ca
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SemBioSys announces senior management changes
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. SemBioSys begins phase I/II trial of insulin produced in plant seeds
4. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
5. SemBioSys announces second quarter 2008 financial and operational results
6. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
7. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
8. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
9. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
10. SemBioSys announces first quarter 2008 financial and operational results
11. SemBioSys receives milestone payments from AVAC Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... The Graphene Opportunity - A Rational ... Is Graphene The New Nanotech? A similar ... predictions of applications ranging from microelectronics to water ... today announced the availability of the Graphene Opportunity ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ... quarter 2008 financial results on Monday, November 10, ... hold a conference call at 8:00 am ET ... 2008 results. Listeners may access the,call by dialing ...
... 30 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) ... Foundation Health Plan, Inc., America,s largest,non-profit health ... in the world. The agreement is for ... sampling consumables (FilterLine(R))., With this agreement, ...
... ... Guidance of $0.90 - $1.10 for 2009 and $1.50 - $1.70 ... for 2010, PITTSBURGH, Oct. 30 ... months ended,Sept. 30, 2008., Financial Highlights, -- Adjusted diluted EPS of $0.23 and $0.52 ...
Cached Biology Technology:Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 2Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14
(Date:8/27/2014)... of consumers are willing to pay a premium for ... they,re getting what the label claims is another matter. ... a new way to make sure farms are labelling ... Journal of Agricultural and Food Chemistry , could ... Bavarian Health and Food Safety Authority and the Wuerzburg ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... are greedy bird-brains, University of Warwick research finds ... they make risky decisions, new research has shown. , ... of Warwick,s Department of Psychology, conducted tests that found ... likely to gamble for high-value than low-value rewards. , ... that the test results show the important role that ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2
... and the U.S.A., the scientists have shown how cutting-edge ... of active proteins in cell organelles at a particular ... use proteins. The work is published in the journal ... cities. They contain all the necessary parts that allow ...
... the use of liquid crystalline polymers (LCP) as a ... sought-after lab-on-a-chip technology. , University of Alberta researchers, collaborating ... Phillips Research Laboratories in the Netherlands, have shown that ... glass backing, can be fabricated and patterned on a ...
... of dengue fever wax and wane over a period ... why. With the incidence and range of the potentially ... these epidemics has never been more important. , A ... suggests that a brief period of cross-immunity conferred by ...
Cached Biology News:A catalogue of proteins 2Polymers show promise for lab-on-a-chip technology 2UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3
Request Info...
Request Info...
Detect and measure levels of mouse IgG2b antibody isotypes quickly and easily....
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Biology Products: